View of Abiraterone vs. docetaxel for metastatic hormone-sensitive prostate cancer: A microsimulation model

Return to Article Details Abiraterone vs. docetaxel for metastatic hormone-sensitive prostate cancer: A microsimulation model Download Download PDF